Equities

Karolinska Development AB

Karolinska Development AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)1.29
  • Today's Change0.00 / 0.00%
  • Shares traded159.35k
  • 1 Year change-16.56%
  • Beta0.5505
Data delayed at least 15 minutes, as of Sep 19 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Karolinska Development AB had revenues fall -12.43% from 2.30m to 2.01m, though the company grew net income from a loss of 88.12m to a gain of 5.39m.
Gross margin--
Net profit margin-296.85%
Operating margin-732.11%
Return on assets-0.45%
Return on equity-0.46%
Return on investment-0.46%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Karolinska Development AB fell by 45.81m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 25.02m for operations while cash used for investing totalled 19.98m.
Cash flow per share-0.0175
Price/Cash flow per share--
Book value per share4.56
Tangible book value per share4.56
More ▼

Balance sheet in SEKView more

Karolinska Development AB has little financial risk as the capital structure does not rely on leverage.
Current ratio4.71
Quick ratio--
Total debt/total equity0.0021
Total debt/total capital0.0021
More ▼

Growth rates in SEK

Year on year, growth in earnings per share excluding extraordinary items increased 105.83%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
EPS growth(5 years)-45.66
EPS (TTM) vs
TTM 1 year ago
86.34
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.